Embecta Corp
NASDAQ:EMBC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Embecta Corp
NASDAQ:EMBC
|
US |
|
G
|
Gibraltar Industries Inc
XMUN:GI2
|
US |
|
A
|
Albis Leasing AG
XHAM:ALG
|
DE |
|
Bechtle AG
F:BC8
|
DE |
|
Sagimet Biosciences Inc
F:0O2
|
US |
|
G
|
Goodland Group Ltd
SGX:5PC
|
SG |
|
J
|
JAS Asset PCL
SET:J
|
TH |
|
F
|
First Solar Inc
XMUN:F3A
|
US |
|
P
|
PPL Corp
F:PP9
|
US |
|
Yojee Ltd
F:SRC
|
AU |
Intrinsic Value
Is EMBC undervalued or overvalued?
See the intrinsic value estimate for Embecta Corp and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
EMBC looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with EMBC’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Embecta Does
Embecta Corp makes disposable insulin delivery products for people with diabetes. Its core products are pen needles, syringes, and other accessories used to inject insulin safely and accurately. The company’s customers are mainly pharmacies, distributors, hospitals, diabetes care providers, and other healthcare buyers that sell or supply these products to patients.
- Headquarters
- United States of America US
- Employees
- 1 850
- IPO date
- Mar 21, 2022
Embecta has no economic moat
Embecta Corp lacks an economic moat, leaving it vulnerable to competitive pressures and market challenges.
Read the full moat analysis
Earnings Waterfall
Embecta Corp
The intrinsic value for Embecta Corp (EMBC) under the Base Case is hidden USD.
Compared with the current market price of 6.55 USD, the stock appears hidden.